Lipid storage droplet protein 5 reduces sodium palmitate‑induced lipotoxicity in human normal liver cells by regulating lipid metabolism‑related factors

Ma,Xueqiang; Cheng,Feiyong; Yuan,Keyu; Jiang,Kexiang; Zhu,Tieming

doi:10.3892/mmr.2019.10360

Lipid storage droplet protein 5 reduces sodium palmitate‑induced lipotoxicity in human normal liver cells by regulating lipid metabolism‑related factors

Authors:
- Xueqiang Ma
- Feiyong Cheng
- Keyu Yuan
- Kexiang Jiang
- Tieming Zhu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Zhuji People's Hospital of Zhejiang Province, Zhuji, Zhejiang 311800, P.R. China
Published online on: June 6, 2019 https://doi.org/10.3892/mmr.2019.10360
Pages: 879-886
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lipid storage droplet protein 5 (LSDP5) is specifically expressed in tissues with high oxidative metabolism such as liver and heart. The present study aimed to explored the role of LSDP5 in sodium palmitate‑induced lipotoxicity in LO2 normal human liver cells. LO2 cells were treated with various concentrations of sodium palmitate (25, 50, 75, 100, 125 and 150 µmol/l) for 12, 24 and 48 h, and cell viability was determined by Cell Counting Kit‑8. Subsequently, LO2 cells were exposed to 100 µmol/l sodium palmitate for 48 h to induce lipotoxicity (Model). Lipotoxicity Model LO2 cells were also transfected with pCMV5‑LSDP5 overexpression vector, and reactive oxygen species (ROS) production, mitochondrial membrane potential (MMP) and apoptotic rates were measured. The contents of non‑esterified fatty acid (NEFA), malondialdehyde (MDA) and superoxide dismutase (SOD) were also measured. The expression levels of LSDP5, and apoptosis‑, mitochondrial‑, lipid metabolism‑related factors were detected using reverse transcription‑quantitative polymerase chain reaction and western blot assays. The results indicated that sodium palmitate exposure inhibited cell viability and induced lipotoxicity in LO2 cells. LSDP5 overexpression decreased ROS and apoptotic rates, and reduced NEFA and MDA content. LSDP5 transfection rescued the loss of MMP and elevated SOD content in lipotoxicity Model LO2 cells. In addition, LSDP5 upregulated the expression levels of B‑cell lymphoma‑2, acetyl‑CoA carboxylase1/2 and fatty acid synthase (Fas), whereas the expression levels of activated‑caspase‑3, Bcl‑2‑associated X protein, cytochrome c, cytochrome c oxidase subunits IV, carnitine palmitoyltransferase 1a and peroxisome proliferator‑activated receptors α levels were downregulated. LSDP5 may produce a protective effect on sodium palmitate‑induced lipotoxicity in LO2 cells by regulating lipid metabolism‑related factors.

View Figures

View References

1	Zheng X, Gong L, Luo R, Chen H, Peng B, Ren W and Wang Y: Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis. 16:2022017. View Article : Google Scholar : PubMed/NCBI
2	Fan JG and Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 50:204–210. 2009. View Article : Google Scholar : PubMed/NCBI
3	Angulo P: GI epidemiology: Nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 25:883–889. 2007. View Article : Google Scholar : PubMed/NCBI
4	de Alwis NM and Day CP: Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol. 48 (Suppl 1):S104–S112. 2008. View Article : Google Scholar : PubMed/NCBI
5	Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ and Chutaputti A; Asia-Pacific Working Party for NAFLD, : What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol. 22:794–800. 2007. View Article : Google Scholar : PubMed/NCBI
6	Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 43 (Suppl 1):S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI
7	Garbarino J and Sturley SL: Saturated with fat: New perspectives on lipotoxicity. Curr Opin Clin Nutr Metab Care. 12:110–116. 2009. View Article : Google Scholar : PubMed/NCBI
8	Weiss TS, Lupke M, Ibrahim S, Buechler C, Lorenz J, Ruemmele P, Hofmann U, Melter M and Dayoub R: Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways. PLoS One. 12:e01842822017. View Article : Google Scholar : PubMed/NCBI
9	Kapoor A and Sanyal AJ: Endoplasmic reticulum stress and the unfolded protein response. Clin Liver Dis. 13:581–590. 2009. View Article : Google Scholar : PubMed/NCBI
10	Bellanti F, Mitarotonda D, Tamborra R, Blonda M, Iannelli G, Petrella A, Sanginario V, Iuliano L, Vendemiale G and Serviddio G: Oxysterols induce mitochondrial impairment and hepatocellular toxicity in non-alcoholic fatty liver disease. Free Radic Biol Med. 75 (Suppl 1):S16–S17. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kusminski CM, Shetty S, Orci L, Unger RH and Scherer PE: Diabetes and apoptosis: Lipotoxicity. Apoptosis. 14:1484–1495. 2009. View Article : Google Scholar : PubMed/NCBI
12	Unger RH and Orci L: Lipoapoptosis: Its mechanism and its diseases. Biochim Biophys Acta. 1585:202–212. 2002. View Article : Google Scholar : PubMed/NCBI
13	McCullough AJ: The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 8521–533. (viii)2004. View Article : Google Scholar : PubMed/NCBI
14	Murphy DJ: The biogenesis and functions of lipid bodies in animals, plants and microorganisms. Prog Lipid Res. 40:325–438. 2001. View Article : Google Scholar : PubMed/NCBI
15	Zehmer JK, Huang Y, Peng G, Pu J, Anderson RG and Liu P: A role for lipid droplets in inter-membrane lipid traffic. Proteomics. 9:914–921. 2009. View Article : Google Scholar : PubMed/NCBI
16	Geng F and Guo D: Lipid droplets, potential biomarker and metabolic target in glioblastoma. Intern Med Rev (Wash DC). May 3–2017.(Epub ahead of print). doi: 10.18103/imr.v3i5.443.
17	Bartz R, Zehmer JK, Zhu M, Chen Y, Serrero G, Zhao Y and Liu P: Dynamic activity of lipid droplets: Protein phosphorylation and GTP-mediated protein translocation. J Proteome Res. 6:3256–3265. 2007. View Article : Google Scholar : PubMed/NCBI
18	Brasaemle DL: Thematic review series: Adipocyte biology. The perilipin family of structural lipid droplet proteins: Stabilization of lipid droplets and control of lipolysis. J Lipid Res. 48:2547–2559. 2007. View Article : Google Scholar : PubMed/NCBI
19	Dalen KT, Dahl T, Holter E, Arntsen B, Londos C, Sztalryd C and Nebb HI: LSDP5 is a PAT protein specifically expressed in fatty acid oxidizing tissues. Biochim Biophys Acta. 1771:210–227. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wolins NE, Quaynor BK, Skinner JR, Tzekov A, Croce MA, Gropler MC, Varma V, Yao-Borengasser A, Rasouli N, Kern PA, et al: OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes. 55:3418–3428. 2006. View Article : Google Scholar : PubMed/NCBI
21	Yamaguchi T, Matsushita S, Motojima K, Hirose F and Osumi T: MLDP, a novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated by peroxisome proliferator-activated receptor alpha. J Biol Chem. 281:14232–14240. 2006. View Article : Google Scholar : PubMed/NCBI
22	Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, Charpentier G, Auclair M, Delépine M, Barroso I, et al: Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med. 364:740–748. 2011. View Article : Google Scholar : PubMed/NCBI
23	Tansey JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, Gavrilova O, Reitman ML, Deng CX, Li C, Kimmel AR and Londos C: Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA. 98:6494–6499. 2001. View Article : Google Scholar : PubMed/NCBI
24	Cao J, Feng XX, Yao L, Ning B, Yang ZX, Fang DL and Shen W: Saturated free fatty acid sodium palmitate-induced lipoapoptosis by targeting glycogen synthase kinase-3β activation in human liver cells. Dig Dis Sci. 59:346–357. 2014. View Article : Google Scholar : PubMed/NCBI
25	Li F, Gu Y, Dong W, Li H, Zhang L, Li N, Li W, Zhang L, Song Y, Jiang L, et al: Cell death-inducing DFF45-like effector, a lipid droplet-associated protein, might be involved in the differentiation of human adipocytes. FEBS J. 277:4173–4183. 2010. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Bhala N, Younes R and Bugianesi E: Epidemiology and natural history of patients with NAFLD. Curr Pharm Des. 19:5169–5176. 2013. View Article : Google Scholar : PubMed/NCBI
28	Cao J, Dai DL, Yao L, Yu HH, Ning B, Zhang Q, Chen J, Cheng WH, Shen W and Yang ZX: Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway. Mol Cell Biochem. 364:115–129. 2012. View Article : Google Scholar : PubMed/NCBI
29	Malhi H and Gores GJ: Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 28:360–369. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ning B, Bai M and Shen W: Reduced glutathione protects human hepatocytes from palmitate-mediated injury by suppressing endoplasmic reticulum stress response. Hepatogastroenterology. 58:1670–1679. 2011. View Article : Google Scholar : PubMed/NCBI
31	Cao SS and Kaufman RJ: Targeting endoplasmic reticulum stress in metabolic disease. Expert Opin Ther Targets. 17:437–448. 2013. View Article : Google Scholar : PubMed/NCBI
32	Li H, Song Y, Zhang LJ, Gu Y, Li FF, Pan SY, Jiang LN, Liu F, Ye J and Li Q: LSDP5 enhances triglyceride storage in hepatocytes by influencing lipolysis and fatty acid β-oxidation of lipid droplets. PLoS One. 7:e367122012. View Article : Google Scholar : PubMed/NCBI
33	Kuramoto K, Okamura T, Yamaguchi T, Nakamura TY, Wakabayashi S, Morinaga H, Nomura M, Yanase T, Otsu K, Usuda N, et al: Perilipin 5, a lipid droplet-binding protein, protects heart from oxidative burden by sequestering fatty acid from excessive oxidation. J Biol Chem. 287:23852–23863. 2012. View Article : Google Scholar : PubMed/NCBI
34	Engin A: Non-alcoholic fatty liver disease. Adv Exp Med Biol. 960:443–467. 2017. View Article : Google Scholar : PubMed/NCBI
35	Kishikawa N and Kuroda N: Chemiluminescence assay for the investigation of reactive oxygen species generator. Yakugaku Zasshi. 135:191–196. 2015.(In Japanese). View Article : Google Scholar : PubMed/NCBI
36	Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD and Gores GJ: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 125:437–443. 2003. View Article : Google Scholar : PubMed/NCBI
37	Schattenberg JM, Galle PR and Schuchmann M: Apoptosis in liver disease. Liver Int. 26:904–911. 2006. View Article : Google Scholar : PubMed/NCBI
38	Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen Y, Chen H, Chu F and Zhang Y: Luteolin promotes cell apoptosis by inducing autophagy in hepatocellular carcinoma. Cell Physiol Biochem. 43:1803–1812. 2017. View Article : Google Scholar : PubMed/NCBI
39	Diamantis A, Magiorkinis E, Sakorafas GH and Androutsos G: A brief history of apoptosis: From ancient to modern times. Onkologie. 31:702–706. 2008.PubMed/NCBI
40	Granneman JG, Moore HP, Mottillo EP and Zhu Z: Functional interactions between Mldp (LSDP5) and Abhd5 in the control of intracellular lipid accumulation. J Biol Chem. 284:3049–3057. 2009. View Article : Google Scholar : PubMed/NCBI
41	Wang H, Bell M, Sreenivasan U, Hu H, Liu J, Dalen K, Londos C, Yamaguchi T, Rizzo MA, Coleman R, et al: Unique regulation of adipose triglyceride lipase (ATGL) by perilipin 5, a lipid droplet-associated protein. J Biol Chem. 286:15707–15715. 2011. View Article : Google Scholar : PubMed/NCBI
42	Mansour M, Schwartz D, Judd R, Akingbemi B, Braden T, Morrison E, Dennis J, Bartol F, Hazi A, Napier I and Abdel-Mageed AB: Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol. 38:537–546. 2011. View Article : Google Scholar : PubMed/NCBI